« Return to News | Drug Sponsors

Mallinckrodt to acquire CNS Therapeutics

Tuesday, September 25, 2012 10:31 AM

Mallinckrodt, the pharmaceuticals business of Covidien, a global healthcare products company, has agreed to acquire CNS Therapeutics, a St. Paul, Minn.-based specialty pharmaceutical company focused on neurological disorders and intractable chronic pain.

Mallinckrodt will acquire all of the outstanding capital stock of CNS Therapeutics for approximately $100 million. The transaction, subject to customary closing conditions, is expected to be completed during the Q4 2012. CNS currently has one marketed product and a diverse pipeline of pain and spasticity products in development.

"This acquisition supports our strategy of leveraging our therapeutic expertise and our core capabilities in manufacturing, regulatory and commercialization to serve patients," said Mark Trudeau, president of pharmaceuticals, Mallinckrodt. "CNS Therapeutics' marketed product line complements our branded portfolio. Their central nervous system and pain management products in development complement our pipeline and address an important need for patients."

Mallinckrodt is the largest U.S. supplier of opioid pain medications and among the top 10 generic pharmaceuticals manufacturers in the U.S., based on prescriptions. Last December, Covidien announced that it planned to spin off Mallinckrodt into a stand-alone company, a process that is expected to be completed in mid-2013.

Covidien does not expect the acquisition to have a material impact on its fiscal 2013 sales or earnings per share.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.